Skip to content

Quorn in Community Health Experiment

Quorn in Community Health Experiment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04773483
Acronym
QUICHE
Enrollment
82
Registered
2021-02-26
Start date
2020-11-09
Completion date
2021-12-17
Last updated
2023-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Brief summary

In overweight individuals (BMI \> 27.5 kg/m2), does daily consumption of mycoprotein containing Quorn Food products lower blood cholesterol compared with daily meat/fish consumption?

Interventions

DIETARY_SUPPLEMENTQuorn Foods products

180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)

DIETARY_SUPPLEMENTMeat/fish products

Standard meat/fish products matched to Quorn group for protein intake

Sponsors

Marlow Foods Ltd
CollaboratorUNKNOWN
NIHR Exeter Clinical Research Facility
CollaboratorNETWORK
University of Exeter
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-70 years old * BMI \>27.5 kg/m2 * Non allergic to penicillin/mycoprotein * Moderate levels of physical activity or below (self-identified; NDNS servey) * Omnivores * Not currently using cholesterol lowering medication

Exclusion criteria

* \<18 or \>70 years old * BMI \<27.5 kg/m2 * Allergies to penicillin/mycoprotein * Heavy exercisers (self idenfiied) * Vegetarian/vegans * Currently using cholesterol lowering medication

Design outcomes

Primary

MeasureTime frameDescription
Postabsorptive blood cholesterol (free, total, LDL, HDL) concentrations4 weeksTest for intervention vs control differences in postabsorptive blood cholesterol levels (mMol) pre and post intervention

Secondary

MeasureTime frameDescription
Fingerprick blood glucose concentration4 weeksTest for intervention vs control differences in blood glucose concentration (mMol) in postabsorptive and postprandial state
Satiety4 weeksTest for intervention vs control differences in satiety using a 10 centimetre 'Satiety Visual Analogue Scale' ratings, anchored by minimum to maximum response for a given aspect of satiety, where 0 cm is minimum and 10 cm is maximum
Hedonic visual analogue scale4 weeksTest for intervention vs control differences and changes in hedonic response using 10 cm 'Hedonic Visual Analogue Scale' ratings, anchored by minimum to maximum response for a given aspect of hedonic response, where 0 cm is minimum and 10 cm is maximum
Postprandial blood cholesterol concentration3 hoursTest for intervention vs control differences in postprandial blood cholesterol levels (mMol) pre and post intervention
Fingerprick blood c-peptide4 weeksTest for intervention vs control differences in C-peptide concentration (ng/ml) in postabsorptive and postprandial state
Fingerprick blood triglyceride concentration4 weeksTest for intervention vs control differences in blood triglyceride concentration (mMol) in postabsorptive and postprandial state
Gastrointestinal side-effectsOnce weekly, over 4 weeksTest for intervention vs control differences in tolerance of diet

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026